Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

189 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-02

Study Completion Date

2026-09-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

.The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are:

* to define a threshold value for each of the plasma,
* to describe the correlations between the plasma biomarkers of interest and the other biological analyses performed as part of care, in particular triglyceridemia, cholesterolemia, glycemia and proteinemia,
* to describe biomarker results in relation to comorbidities, in particular dyslipidemia and diabetes
* to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A/T/N classification (A-/T+ or A+/T-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New CSF Biomarkers for Alzheimer's Disease

NCT03621839

Alzheimer Disease Dementia Neurodegenerative Diseases

RECRUITING

Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers

NCT07071649

Alzheimer's Disease Biomarkers Non-invasive Diagnosis +1 more

RECRUITING NA

Cerebro Spinal Fluid Collection (CSF)

NCT04844060

Alzheimer Disease Dementia With Lewy Bodies Frontotemporal Dementia +2 more

RECRUITING

Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers

NCT06561906

Alzheimer Disease, Late Onset Mild Cognitive Impairment Subjective Cognitive Decline

RECRUITING

Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults

NCT03129269

Frail Elderly

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Blood Biomarkers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood ponction

All patients are in the experimental group

Group Type EXPERIMENTAL

Blood ponction

Intervention Type DIAGNOSTIC_TEST

Blood ponction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood ponction

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman aged 18 or over
* Person affiliated to a social security scheme or beneficiary of such a scheme
* Person who has received full information on the organization of the research and has signed an informed consent form
* Person whose care requires a lumbar puncture to measure markers of Alzheimer's disease

Exclusion Criteria

* Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
* An adult unable to give consent
* Persons deprived of their liberty by judicial or administrative decision
* Persons under psychiatric care under articles L. 3212-1 and L. 3213-1.
* Pregnant, parturient or breast-feeding women
* Persons staying in a health or social establishment for purposes other than research.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No